Capstone Investment Advisors
BIO icon

Capstone Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capstone Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$3.23M – 2346
2023
Q4 		$3.23M Buy
+10,000
New +$3.13M 0.01% 664

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capstone Investment Advisors's BIO Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 5,907 shares — an estimated $1.66M sold.

Capstone Investment Advisors first reported a position in BIO in Q3 2017 and held it in 4 quarters. The position peaked at $1.66M in Q3 2025. 397 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 5,907 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $1.66M.
  • Capstone Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2017 and held it in 4 quarters.
  • Capstone Investment Advisors's Bio-Rad Laboratories Class A position peaked at $1.66M in Q3 2025.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.